Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03509883 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT03509883 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 94 participants.
The verdict
NCT03509883, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose of apixaban twice during the course of the study.
Interventions
- DRUG Drug: Apixaban sprinkle capsules
- DRUG Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03509883
The ClinicalTrials.gov registry entry for NCT03509883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drug: Apixaban sprinkle capsules is the first listed.
NCT03509883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03509883 about?
NCT03509883 is a clinical study titled "Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules". The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose o...
What is the current status of trial NCT03509883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2018-04-26. Estimated completion is 2018-06-15.
What interventions are being tested in trial NCT03509883?
The interventions under investigation include: Drug: Apixaban sprinkle capsules (DRUG), Experimental: Apixaban tablets followed by apixaban sprinkle capsules (DRUG).
Who is sponsoring clinical trial NCT03509883?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.